# DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

> **NCT06158269** · PHASE2 · RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** DVRd

## Key facts

- **NCT ID:** NCT06158269
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158269, "DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06158269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*